In summary, by dissecting ceramide/sphingosine-I2PP2A/SET signalling, we identified that I2PP2A/SET is a novel drug target in human lung tumours and, more importantly, that it can be specifically targeted by the sphingosine analogue FTY720 leading to PP2A activation and RIPK1-dependent tumour necroptosis. This evidence concerns the gene PTPA and neoplasm.